Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclatasvir plus Sofosbuvir in HIV/HCV Coinfection
NCT02032888Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daclatasvir in hepatitis C (HCV) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Sustained Virologic Response at Follow-up Week 12. Started Feb 2014; status: completed.
02
Drugs
daclatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02032888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02032888.